The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Ligand efficiency indices for effective drug discovery
Abstract
Successful drug discovery requires the optimization of a large number of variables ranging from strictly physicochemical parameters such as molecular weight to more complex parameters related to toxicity and bioavailability. Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclinical characterization. However, critical biological issues along the path to the market have diminished the impact and power of this methodology. The physicochemical properties of the novel chemical entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate. The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process. More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context. Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
The Genome Sequence of Drosophila melanogaster
Adams, M. D., Celniker, S. E., Holt, R. A., Evans, C. A., Gocayne, J. D., Amanatides, P. G., Scherer, S. E., Li, P. W., Hoskins, R. A., Galle, R. F., et al. (2000) · Science · doi:10.1126/science.287.5461.2185 · Cited by 5,929
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
The Properties of Known Drugs. 1. Molecular Frameworks
Bemis, G. W., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9602928 · Cited by 2,482
Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects
Sherman, W., Day, T., Jacobson, M. P., Friesner, R. A., & Farid, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050540c · Cited by 2,031
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
A Critical Assessment of Docking Programs and Scoring Functions
Warren, G. L., Andrews, C. W., Capelli, A.-M., Clarke, B., LaLonde, J., Lambert, M. H., Lindvall, M., Nevins, N., Semus, S. F., Senger, S., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050362n · Cited by 1,814
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020
The maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans
Palm, K., Stenberg, P., Luthman, K., & Artursson1, P. (1997) · Pharmaceutical Research · doi:10.1023/a:1012188625088 · Cited by 756
Use of an Induced Fit Receptor Structure in Virtual Screening
Sherman, W., Beard, H. S., & Farid, R. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2005.00327.x · Cited by 697
Prediction of Protein−Ligand Interactions. Docking and Scoring: Successes and Gaps
Leach, A. R., Shoichet, B. K., & Peishoff, C. E. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060999m · Cited by 646
Vedadi, M., Niesen, F. H., Allali-Hassani, A., Fedorov, O. Y., Finerty, P. J., Wasney, G. A., Yeung, R., Arrowsmith, C., Ball, L. J., Berglund, H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605224103 · Cited by 589
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Self-citationDruggability Indices for Protein Targets Derived from NMR-Based Screening Data
Hajduk, P. J., Huth, J. R., & Fesik, S. W. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049131r · Cited by 522
Roehrig, S., Straub, A., Pohlmann, J., Lampe, T., Pernerstorfer, J., Schlemmer, K.-H., Reinemer, P., & Perzborn, E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050101d · Cited by 436
A Scoring Scheme for Discriminating between Drugs and Nondrugs
Sadowski, J., & Kubinyi, H. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9706776 · Cited by 392
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Keynote review: Structural biology and drug discovery
Congreve, M., Murray, C. W., & Blundell, T. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03484-7 · Cited by 338
Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR
Hajduk, P. J., Sheppard, G., Nettesheim, D. G., Olejniczak, E. T., Shuker, S. B., Meadows, R. P., Steinman, D. H., Carrera, G. M., Marcotte, P. A., Severin, J., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9702778 · Cited by 317
Fragment-Based Drug Design: How Big Is Too Big?
Hajduk, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060511h · Cited by 265
Hit discovery and hit-to-lead approaches
Keserű, G. M., & Makara, G. M. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.016 · Cited by 256
Drugs, leads, and drug-likeness: an analysis of some recently launched drugs
Proudfoot, J. R. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00244-5 · Cited by 252
Szczepankiewicz, B. G., Liu, G., Hajduk, P. J., Abad-Zapatero, C., Pei, Z., Xin, Z., Lubben, T. H., Trevillyan, J. M., Stashko, M. A., Ballaron, S. J., et al. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0296733 · Cited by 231
Self-citationPearlman, D. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050306m · Cited by 193
Fragment‐based Approaches in Drug Discovery
(2006) · Methods and Principles in Medicinal Chemistry · doi:10.1002/3527608761 · Cited by 181
Iversen, L. F., Andersen, H. S., Branner, S., Mortensen, S. B., Peters, G. H., Norris, K., Olsen, O. H., Jeppesen, C. B., Lundt, B. F., Ripka, W., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10300 · Cited by 168
Fragment screening: an introduction
Leach, A. R., Hann, M. M., Burrows, J. N., & Griffen, E. J. (2006) · Molecular BioSystems · doi:10.1039/b610069b · Cited by 163
Liu, G., Xin, Z., Pei, Z., Hajduk, P. J., Abad-Zapatero, C., Hutchins, C. W., Zhao, H., Lubben, T. H., Ballaron, S. J., Haasch, D. L., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034122o · Cited by 162
Self-citationImproving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits
Wunberg, T., Hendrix, M., Hillisch, A., Lobell, M., Meier, H., Schmeck, C., Wild, H., & Hinzen, B. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03700-1 · Cited by 152
Improving the Odds in Discriminating “Drug-like” from “Non Drug-like” Compounds
Frimurer, T. M., Bywater, R. P., Nærum, L., Nørskov‐Lauritsen, L., & Brunak, S. (2000) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0003810 · Cited by 129
Virtual Screening against Metalloenzymes for Inhibitors and Substrates
Irwin, J. J., Raushel, F. M., & Shoichet, B. K. (2005) · Biochemistry · doi:10.1021/bi050801k · Cited by 127
Morphy, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512185 · Cited by 123
Liu, G., Xin, Z., Liang, H., Abad‐Zapatero, C., Hajduk, P. J., Janowick, D. A., Szczepankiewicz, B. G., Pei, Z., Hutchins, C. W., Ballaron, S. J., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034088d · Cited by 109
Self-citationTaking MAD to the extreme: ultrafast protein structure determination
Walsh, M. A., Dementieva, I. S., Evans, G., Sanishvili, R., & Joachimiak, A. (1999) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444999003698 · Cited by 107
Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs
Vieth, M., & Sutherland, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603825 · Cited by 103
Drug Guru: A computer software program for drug design using medicinal chemistry rules
Stewart, K. D., Shiroda, M., & James, C. A. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.06.024 · Cited by 103
Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors
Zhao, H., Liu, G., Xin, Z., Serby, M. D., Pei, Z., Szczepankiewicz, B. G., Hajduk, P. J., Abad‐Zapatero, C., Hutchins, C. W., Lubben, T. H., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.063 · Cited by 84
Self-citationComputational chemistry-driven decision making in lead generation
Schnecke, V., & Boström, J. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03703-7 · Cited by 77
Science, art and drug discovery: a personal perspective
Campbell, S. F. (2000) · Clinical Science · doi:10.1042/cs0990255 · Cited by 75
Liu, G., Szczepankiewicz, B. G., Pei, Z., Janowick, D. A., Xin, Z., Hajduk, P. J., Abad‐Zapatero, C., Liang, H., Hutchins, C. W., Fesik, S. W., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0205696 · Cited by 64
Self-citationInhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity
Pei, Z., Liu, G., Lubben, T. H., & Szczepankiewicz, B. G. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382954 · Cited by 64
Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase
Lai, C., Gum, R. J., Daly, M. M., Fry, E. H., Hutchins, C. W., Abad‐Zapatero, C., & von Geldern, T. W. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.014 · Cited by 62
Self-citationvon Geldern, T. W., Lai, C., Gum, R. J., Daly, M. M., Sun, C. C., Fry, E. H., & Abad‐Zapatero, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.015 · Cited by 60
Self-citationPotent, selective inhibitors of protein tyrosine phosphatase 1B
Xin, Z., Oost, T. K., Abad‐Zapatero, C., Hajduk, P. J., Pei, Z., Szczepankiewicz, B. G., Hutchins, C. W., Ballaron, S. J., Stashko, M., Lubben, T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00302-0 · Cited by 49
Self-citationIdentification of “Latent Hits” in Compound Screening Collections
Mestres, J., & Veeneman, G. H. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034078c · Cited by 43
Current state and prospects of macromolecular crystallography
Dauter, Z. (2005) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905034050 · Cited by 38
Protein Data Bank depositions from synchrotron sources
Jiang, J., & Sweet, R. M. (2004) · Journal of Synchrotron Radiation · doi:10.1107/s0909049504013792 · Cited by 33
Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors
Pei, Z., Li, X., Liu, G., Abad‐Zapatero, C., Lubben, T., Zhang, T., Ballaron, S. J., Hutchins, C. W., Trevillyan, J. M., & Jirousek, M. R. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00725-x · Cited by 24
Self-citation
Cited by
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Fsp3: A new parameter for drug-likeness
Wei, W., Cherukupalli, S., Jing, L., Liu, X., & Zhan, P. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.017 · Cited by 421
Metadata
- Authors
- Abad-Zapatero, C.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2007-04
- Volume
- 2
- Issue
- 4
- Pages
- 469-488
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2103299776
- Cited by
- 279
- References
- 56
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.